From predicate device selection through FDA clearance — expert 510(k) consulting for medical device companies navigating the premarket notification process. We build submissions that clear on the first review cycle.
Jared Clark, JD, MBA, PMP, CMQ-OE, RAC, CPGP, CFSQA
510(k) consulting is a core specialty of The FDA Expert, the medical device regulatory practice of Certify Consulting.
A 510(k) — formally known as a premarket notification — is a regulatory submission made to the U.S. Food and Drug Administration to demonstrate that a new medical device is substantially equivalent to a legally marketed device (called a predicate device). The 510(k) pathway is authorized under Section 510(k) of the Federal Food, Drug, and Cosmetic Act and is the most common route to market for Class II medical devices in the United States.
The FDA receives more than 3,000 510(k) submissions annually. Unlike the PMA (Premarket Approval) pathway, which requires clinical evidence of safety and effectiveness, the 510(k) pathway relies on demonstrating that your device is at least as safe and effective as a device that is already legally marketed. This makes the 510(k) faster and less expensive than PMA — but the submission still requires rigorous scientific evidence, detailed technical documentation, and precise regulatory strategy.
Not every medical device qualifies for the 510(k) pathway. The determination depends on your device's classification (Class I, II, or III), whether a suitable predicate device exists, and whether your device raises new questions of safety or effectiveness that a predicate comparison cannot address. Getting this determination right at the start of your project is critical — choosing the wrong pathway wastes months and hundreds of thousands of dollars.
Key distinction: FDA 510(k) clearance is not the same as FDA approval. Cleared devices have demonstrated substantial equivalence to a predicate. Approved devices (via PMA) have demonstrated safety and effectiveness through clinical evidence. The legal and marketing implications of this distinction matter. Our FDA 510(k) consultants help you navigate the correct regulatory language and pathway from day one.
The entire 510(k) submission hinges on one concept: substantial equivalence (SE). Your device must be compared to one or more legally marketed predicate devices and shown to be substantially equivalent in both intended use and technological characteristics. FDA's determination of substantial equivalence is the basis for clearance.
The FDA evaluates substantial equivalence through a structured decision framework:
The substantial equivalence comparison is documented in the SE discussion section of your 510(k) submission — often the most scrutinized section by FDA reviewers. A weak SE argument is the single most common reason for 510(k) rejections, Additional Information (AI) requests, and Not Substantially Equivalent (NSE) determinations.
Common pitfall: Many manufacturers choose a predicate based on superficial similarity rather than regulatory defensibility. Your predicate strategy should be driven by intended use alignment, classification match, and the testing burden each predicate implies. We conduct exhaustive predicate searches across FDA databases before committing to a comparison strategy.
Predicate device selection is arguably the most important strategic decision in the 510(k) process. The predicate you choose dictates the scope of testing required, the strength of your substantial equivalence argument, and ultimately whether the FDA clears your device.
Our FDA 510(k) consultants conduct comprehensive predicate research across multiple FDA databases:
Your 510(k) can reference one primary predicate (the device to which you make the direct SE comparison) and one or more reference predicates (additional devices that support specific aspects of your comparison, such as a particular technology or material). Strategic use of reference predicates can strengthen your submission when no single predicate perfectly matches your device.
Our approach: We never commit to a predicate strategy without first validating it through internal review. For complex devices, we recommend confirming the predicate selection with FDA through a pre-submission (Q-Sub) meeting before investing in testing — this eliminates the risk of building an entire submission around a predicate the FDA rejects.
A structured, phase-based approach to 510(k) clearance — from initial device assessment through FDA decision. No guesswork, no surprises.
We evaluate your device's intended use, technology, classification, and risk profile to confirm 510(k) is the correct regulatory pathway — and identify alternatives (De Novo, PMA) if it is not.
Exhaustive search across FDA databases to identify and evaluate predicate device candidates. We assess each option for intended use match, technology alignment, and testing implications.
We prepare and submit a pre-submission request to obtain FDA feedback on your predicate strategy, testing plan, and regulatory approach before committing to full testing.
We define testing protocols, coordinate with accredited labs, and manage performance testing, biocompatibility (ISO 10993), software validation (IEC 62304), and any other required evidence.
We compile the complete 510(k) submission — including device description, SE comparison, performance data, labeling, and all supporting documentation — formatted to FDA's eSTAR template.
We manage the FDA review process, respond to Additional Information (AI) requests, and guide you through to the Substantially Equivalent (SE) determination and 510(k) clearance letter.
Performance testing provides the scientific evidence that supports your substantial equivalence claim. The scope and type of testing required depend on your device's classification, the differences between your device and its predicate, and any applicable FDA guidance documents or recognized consensus standards.
Bench testing evaluates your device's physical, mechanical, chemical, and electrical performance characteristics under controlled laboratory conditions. Common bench tests include tensile strength, fatigue testing, dimensional analysis, coating adhesion, electrical safety (IEC 60601), and sterility assurance. The specific tests required are driven by your device type, applicable FDA guidance, and the performance characteristics that must match or exceed the predicate.
Any device that contacts the body — whether externally, internally, or through the blood path — must undergo biocompatibility evaluation per the ISO 10993 series. The required tests are determined by the nature and duration of body contact, as outlined in ISO 10993-1 and FDA's guidance on Use of International Standard ISO 10993-1. Common endpoints include:
Biocompatibility testing is one of the most significant cost drivers in a 510(k) project. A thorough biological evaluation plan based on your device's specific contact characteristics can optimize the testing scope — avoiding unnecessary tests while ensuring FDA acceptance. In some cases, a biocompatibility risk assessment based on material characterization and existing data may reduce the need for full animal testing.
Medical devices that contain software — including Software as a Medical Device (SaMD) — must include software documentation in the 510(k) submission. The FDA expects software lifecycle documentation aligned with IEC 62304 (Medical device software — Software life cycle processes) and consistent with FDA's guidance on Content of Premarket Submissions for Device Software Functions.
Required software documentation typically includes:
The level of documentation required scales with the device's software safety classification under IEC 62304 (Class A, B, or C) and the Level of Concern as defined in FDA guidance. Software-related deficiencies are among the most common reasons for Additional Information (AI) requests during 510(k) review.
Testing strategy matters: We develop a comprehensive testing plan before any testing begins, aligned with FDA expectations and your predicate comparison. This prevents expensive re-testing, ensures lab reports meet FDA formatting requirements, and keeps your project on timeline and on budget.
The FDA has specific requirements for how 510(k) submissions must be organized, formatted, and submitted. Since 2023, the FDA has required most 510(k) submissions to use the eSTAR (electronic Submission Template and Resource) format — a structured, fillable PDF template that standardizes submission content and improves review efficiency.
A complete 510(k) submission typically includes the following sections:
The eSTAR template organizes submission content into a structured electronic format that FDA reviewers can navigate efficiently. Since October 2023, the FDA has required eSTAR format for all 510(k) submissions. Submissions that do not use eSTAR may be placed on Refuse to Accept (RTA) hold, delaying your review by weeks or months.
Our FDA 510(k) consultants are experienced with the eSTAR template and ensure that every section is completed accurately, all required attachments are properly formatted and linked, and the submission passes FDA's acceptance review without RTA issues.
Refuse to Accept (RTA): The FDA conducts an acceptance review within 15 business days of receiving your 510(k). If the submission is missing required elements, improperly formatted, or uses an incorrect template, the FDA issues an RTA hold. This stops the review clock and can add 30–60 days to your timeline. Our pre-submission quality check prevents RTA holds.
Understanding the FDA's 510(k) review process and timeline is essential for project planning and investor/stakeholder communication. The review follows a structured sequence with defined milestones.
Within 15 business days of receiving your submission, the FDA conducts an acceptance review to verify that all required elements are present and the submission is administratively complete. If the submission passes, the review clock officially starts. If it fails, you receive an RTA (Refuse to Accept) hold notification.
The FDA reviewer evaluates the technical merits of your submission — the device description, substantial equivalence comparison, performance data, labeling, and all supporting documentation. During this phase, the reviewer may issue an Additional Information (AI) request asking for clarification, additional data, or supplementary analysis. AI requests pause the review clock until you respond.
Under the Medical Device User Fee Amendments (MDUFA), the FDA's target is to issue a decision within 90 FDA days of acceptance. The possible outcomes are:
While FDA's review target is 90 days, the total project timeline from initial assessment to clearance is typically 6 to 12 months. This includes:
Factors that extend the timeline include AI requests from FDA, complex software documentation requirements, clinical data needs, and delays in testing laboratory schedules. Our project management approach — backed by PMP-certified project discipline — keeps all workstreams coordinated and on track.
Timeline optimization: The biggest timeline savings come from early strategic decisions. A well-chosen predicate, a validated testing plan confirmed through Q-Sub, and a submission that passes RTA on the first attempt can shave months off your total project timeline. That is exactly what our 510(k) consulting delivers.
A pre-submission (Q-Sub) is a formal mechanism for obtaining FDA feedback before you submit your 510(k). The FDA's Guidance on Requests for Feedback and Meetings for Medical Device Submissions (the Q-Sub guidance) outlines the process for requesting a pre-submission meeting with the FDA review team that will evaluate your eventual 510(k).
The pre-submission meeting is one of the most valuable tools in the 510(k) process. It allows you to:
The Q-Sub process follows a defined timeline:
Our recommendation: We advise a Q-Sub for nearly every 510(k) engagement. The 75-day investment upfront frequently saves 3–6 months on the back end by preventing AI requests, predicate rejections, and testing gaps that would otherwise derail the FDA review. The cost of a Q-Sub is negligible compared to the cost of a failed or delayed submission.
While the 510(k) is the most common pathway to market for medical devices, it is not always the right one. Part of our role as your FDA 510(k) consultants is to assess whether an alternative pathway may be more appropriate — and to guide you through it if so.
The De Novo classification request (Section 513(f)(2) of the FD&C Act) is designed for novel, low-to-moderate risk devices that have no legally marketed predicate. If your device is genuinely new — with no existing predicate device to compare against — but poses relatively low risk, the De Novo pathway may be the correct route.
A successful De Novo creates a new device classification, complete with a new product code and applicable special controls. Importantly, the De Novo-authorized device then becomes a predicate for future 510(k) submissions by other manufacturers. De Novo review timelines are longer than 510(k) (FDA targets 150 review days), and the submission requirements are more extensive, but the pathway avoids the significantly higher burden of a PMA.
The Premarket Approval (PMA) pathway is required for Class III medical devices — those that support or sustain human life, present a potential unreasonable risk of illness or injury, or are of substantial importance in preventing impairment of human health. PMA requires valid scientific evidence (typically clinical trial data) demonstrating that the device is safe and effective for its intended use.
PMA is the most rigorous and expensive FDA device pathway. Total costs often exceed $500,000 to several million dollars when including clinical trials, and the review process typically takes 180+ FDA days. However, PMA approval provides stronger market protection and broader marketing claims than 510(k) clearance.
Pathway determination: We perform a comprehensive regulatory assessment at the start of every engagement to confirm that the 510(k) pathway is viable. If your device is better suited for De Novo or PMA, we identify this early — before you invest in the wrong strategy. Early pathway determination saves our clients tens of thousands of dollars and months of misdirected effort.
510(k) clearance is one milestone in your device's regulatory lifecycle. Most medical device companies also need support with registration, compliance systems, and ongoing FDA requirements.
Your device establishment must be registered with the FDA and your device listed before you can begin commercial distribution. We handle the complete registration process.
Learn morePost-clearance requirements include QMSR compliance, MDR reporting, UDI labeling, and annual registration renewal. Ongoing compliance management keeps your device on the market.
Learn moreOnce you are manufacturing and distributing your cleared device, FDA inspections are inevitable. Mock inspections, documentation review, and real-time inspection support.
Learn moreCommon questions about the FDA 510(k) process, costs, timelines, and how our consulting services can help your medical device reach market.
Schedule a free consultation with Jared Clark, RAC. Whether you are in the early planning stages or need to rescue a stalled submission — we will help you build a 510(k) that clears.